Business Context and Reporting Period
This Form 8-K filing by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) covers events occurring on April 2 and April 3, 2008. The report details significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure: Gregory P. Hanson ended his employment as Chief Financial Officer, Treasurer, and Senior Vice President on April 2, 2008.
- Appointment: Mark N.K. Bagnall was appointed Chief Financial Officer, Treasurer, and Executive Vice President, effective April 3, 2008.
- Board Changes: Mr. Bagnall resigned from the Audit, Compensation, and Nominating and Governance committees, as well as his role as Audit Committee Chair. Jack Lief was appointed Chair of the Audit Committee.
Compensation, Outlook, and Risks
Compensation Arrangements:
- Base Salary: $350,000 per year.
- Equity Grant: 500,000 stock options granted on April 3, 2008, with an exercise price of $0.52 per share.
- Vesting Schedule: 100,000 shares vest annually on January 1 from 2009 through 2013, subject to continuous service.
- Severance: In the event of involuntary termination, Mr. Bagnall is eligible for salary continuation for a period equal to his tenure (capped at 12 months), health benefits, and 401(k) matching. Receipt of severance requires a general release of claims and resignation from the Board.
- Acceleration Clauses: Options accelerate upon involuntary termination (partial acceleration based on timing) or change of control (full acceleration if not assumed/replaced; 50% immediate vesting if assumed).
Outlook and Risks: The filing contains no forward-looking financial guidance or discussion of general business risks. The primary contingency noted is the requirement for Mr. Bagnall to execute a release of claims to receive severance or accelerated option vesting.
Investor Verification Checklist
- Verify the exact date of Gregory P. Hanson's departure and any potential transition period details not explicitly stated.
- Confirm the total number of outstanding options and the dilution impact of the 500,000 new options granted to Mr. Bagnall.
- Review the definition of "involuntary termination" and "good reason" to understand the triggers for severance and option acceleration.
- Check subsequent filings to confirm Mr. Bagnall's continued tenure and the company's financial status post-appointment.